For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$115.31
Thesis
Kymera is a leading targeted-protein-degradation company applying its platform to immunology and inflammation — degrading disease-driving proteins (STAT6, IRAK4) that conventional small molecules struggle to drug, aiming for oral therapies that compete with injectable biologics. Pharma partnerships (e.g. Sanofi) have validated the platform and helped fund it.
The investment case is platform breadth: one degradation chemistry reused across many immunology targets, with oral convenience as the commercial wedge against biologics. Risks: clinical-stage with the binary readout risk that entails, competition across the degrader field, and value spread across early programs rather than an approved product.
Catalysts
- STAT6 degrader clinical readouts in atopic dermatitis / immunology
- IRAK4 and follow-on program progress
- Partnership economics and option exercises
- Oral-vs-biologic differentiation data
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 2Trial readoutClinicalTrials.gov
Kymera completes Phase 1 first-in-human study of KT-579 in healthy adults (NCT07412288).
- Oct 29Financial resultsSEC
Kymera Therapeutics filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Oct 7Trial initiationClinicalTrials.gov
Kymera starts Phase 2 long-term extension study of KT-621 in prior asthma trial participants (NCT07677059, recruiting)
- Oct 6Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial of KT-621 in moderate to severe eosinophilic asthma (NCT07323654, recruiting).
- Oct 6Trial initiationClinicalTrials.gov
Kymera updates Phase 2 trial NCT07217015 of KT-621 in moderate to severe atopic dermatitis to ACTIVE_NOT_RECRUITING status.
- Aug 17Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status as of 2026-08-17.
- Aug 5Financial resultsSEC
Kymera Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.
- Jul 27LeadershipSEC
8-K filed with items 5.02, 7.01, 9.01 covering officer or director changes and related exhibits.